Hikma and Celltrion Healthcare sign exclusive licensing agreement for ustekinumab for the Middle East and North Africa region

miscellaneous news
By:
On:

London, England — Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces a new exclusive licensing agreements with Celltrion Healthcare Co., Ltd. for CT-P43 (ustekinumab). CT-P43 is a monoclonal antibody that is a proposed biosimilar to Janssen’s Stelara®.   Under the terms of the agreement, Hikma will have exclusive rights toContinue Reading